Lee S Cohen1, Hadine Joffe, Katherine A Guthrie, Kristine E Ensrud, Marlene Freeman, Janet S Carpenter, Lee A Learman, Katherine M Newton, Susan D Reed, Joann E Manson, Barbara Sternfeld, Bette Caan, Ellen W Freeman, Andrea Z LaCroix, Lesley F Tinker, Cathryn Booth-Laforce, Joseph C Larson, Garnet L Anderson. 1. From the 1Massachusetts General Hospital, Boston, MA; 2MsFLASH Data Coordinating Center, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; 3VA Medical Center, University of Minnesota, Minneapolis, MN; 4School of Nursing, Indiana University, Indianapolis, IN; 5Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; 6Group Health Research Institute, Group Health Cooperative, Seattle, WA; 7Departments of Obstetrics/Gynecology and Epidemiology, University of Washington School of Medicine, Seattle, WA; 8Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 9Division of Research, Kaiser Permanente Medical Program of Northern California, Oakland, CA; 10Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA; and 11School of Nursing, University of Washington, Seattle, WA.
Abstract
OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI, -3.0 to -1.9) did not differ significantly from that with placebo (-2.7; 95% CI, -3.3 to -2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI, -0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI, -0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.
RCT Entities:
OBJECTIVE: This study aims to determine the efficacy and tolerability of omega-3 fatty acids in reducing vasomotor symptoms (VMS) frequency and bother in perimenopausal and postmenopausal women. METHODS: This study was a 12-week, three-by-two factorial, randomized controlled trial. Eligible women were randomized to a double-blind comparison of omega-3 (n = 177) or placebo (n = 178) capsules, and simultaneously to yoga (n = 107), aerobic exercise (n = 106), or their usual physical activity (n = 142). Participants received 1.8 g of omega-3 daily for 12 weeks. Each capsule contained ethyl eicosapentaenoic acid (425 mg), docosahexaenoic acid (100 mg), and other omega-3s (90 mg). Primary outcomes were VMS frequency and bother. Secondary outcomes included sleep quality (Pittsburgh Sleep Quality Index), insomnia symptoms (Insomnia Severity Index), depressive symptoms (Physician's Health Questionnaire-8), and anxiety (Generalized Anxiety Disorder-7). RESULTS: The mean baseline frequency of VMS per day was 7.6 (95% CI, 7.0 to 8.2). After 12 weeks, the reduction in VMS frequency with omega-3 (-2.5; 95% CI, -3.0 to -1.9) did not differ significantly from that with placebo (-2.7; 95% CI, -3.3 to -2.2), with a relative difference of 0.3 fewer hot flashes per day (95% CI, -0.5 to 1.0; P = 0.28). Changes in VMS bother at 12 weeks were also similar between groups, with no relative difference on a four-point scale (95% CI, -0.1 to 0.2; P = 0.36). Omega-3s compared with placebo showed no improvement in self-reported sleep or mood (P > 0.09 for all comparisons). CONCLUSIONS: Among healthy, sedentary perimenopausal and postmenopausal women, a 12-week treatment with omega-3 does not improve VMS frequency, VMS bother, sleep, or mood compared with placebo.
Authors: Joyce T Bromberger; Laura L Schott; Howard M Kravitz; Maryfran Sowers; Nancy E Avis; Ellen B Gold; John F Randolph; Karen A Matthews Journal: Arch Gen Psychiatry Date: 2010-06
Authors: Lee Hooper; Rachel L Thompson; Roger A Harrison; Carolyn D Summerbell; Andy R Ness; Helen J Moore; Helen V Worthington; Paul N Durrington; Julian P T Higgins; Nigel E Capps; Rudolph A Riemersma; Shah B J Ebrahim; George Davey Smith Journal: BMJ Date: 2006-03-24
Authors: Karen M Silvers; Cheryl C Woolley; Frances C Hamilton; Peter M Watts; Rosemary A Watson Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2005-03 Impact factor: 4.006
Authors: Kurt Kroenke; Tara W Strine; Robert L Spitzer; Janet B W Williams; Joyce T Berry; Ali H Mokdad Journal: J Affect Disord Date: 2008-08-27 Impact factor: 4.839
Authors: Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix Journal: JAMA Date: 2011-01-19 Impact factor: 157.335
Authors: Janet S Carpenter; James E Tisdale; Joseph C Larson; Ying Sheng; Chen X Chen; Diane Von Ah; Richard Kovacs; Susan D Reed; Rebecca C Thurston; Katherine A Guthrie Journal: Menopause Date: 2021-11-29 Impact factor: 2.953
Authors: Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie Journal: Menopause Date: 2020-04 Impact factor: 2.953
Authors: Salene M W Jones; Katherine A Guthrie; Andrea Z LaCroix; Barbara Sternfeld; Carol A Landis; Susan D Reed; Andrea Dunn; Bette Caan; Lee S Cohen; Julie Hunt; Katherine M Newton Journal: Clin Auton Res Date: 2015-12-21 Impact factor: 5.625
Authors: Katherine A Guthrie; Andrea Z LaCroix; Kristine E Ensrud; Hadine Joffe; Katherine M Newton; Susan D Reed; Bette Caan; Janet S Carpenter; Lee S Cohen; Ellen W Freeman; Joseph C Larson; JoAnn E Manson; Kathy Rexrode; Todd C Skaar; Barbara Sternfeld; Garnet L Anderson Journal: Obstet Gynecol Date: 2015-08 Impact factor: 7.623
Authors: S D Reed; K M Newton; J C Larson; C Booth-LaForce; N F Woods; C A Landis; E Tolentino; J S Carpenter; E W Freeman; H Joffe; B D Anawalt; K A Guthrie Journal: Clin Endocrinol (Oxf) Date: 2016-01-26 Impact factor: 3.523